Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07038733 · ClinicalTrials.gov registry record · NA
Investigation of Lymph Node Biology in Kidney Cancer
A NA study of Renal Cell Carcinoma (RCC), sponsored by Yale University.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07038733: Recruiting NA study of Renal Cell Carcinoma (RCC), sponsored by Yale University.
NCT07038733 is a NA study of Renal Cell Carcinoma (RCC) that is actively recruiting participants, run by Yale University. The registered enrollment target is 10 participants, below the 410-participant average among 12 other Renal Cell Carcinoma (RCC) trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07038733, a NA study of Renal Cell Carcinoma (RCC), is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study is to investigate the phenotype, anti-tumor effector functions, and TCR repertoire of T cells isolated from patient tumor draining lymph nodes (TDLNs) to understand T cell priming and trafficking patterns in Renal Cell Carcinoma (RCC). Data and biospecimen collected will be used for current and future research projects involving the study of kidney cancer biology and related medical conditions. We will use this valuable resource to ask clinically relevant translational questions that pertain to biomarker discovery/validation, identification of novel therapeutic targets, and to better understand the genetic and biological basis of the various kidney cancers.
Primary Outcome
This outcome measure focuses on the detailed molecular characterization of tumor and draining lymph node tissues collected from kidney cancer patients. The analysis will include genomic, transcriptomic, and proteomic profiling to understand the underlying biology of kidney cancers
Conditions Studied
Interventions
- PROCEDURE Peripheral Blood Sample for Immune Analysis
- PROCEDURE Tumor Sample for Analysis
- PROCEDURE Adjacent non-malignant kidney for analysis
- PROCEDURE Draining lymph node(s) for analysis
- PROCEDURE Regional non-draining lymph node(s) for analysis
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-01-30 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT07038733 shows while recruiting
NCT07038733 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 410-participant average among 12 other Renal Cell Carcinoma (RCC) trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Renal Cell Carcinoma (RCC) appearing as the primary indexed condition, and to 5 interventions - of which Peripheral Blood Sample for Immune Analysis is the first listed.
NCT07038733 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT07038733 about?
NCT07038733 is a clinical study titled "Investigation of Lymph Node Biology in Kidney Cancer". The purpose of this pilot study is to investigate the phenotype, anti-tumor effector functions, and TCR repertoire of T cells isolated from patient tumor draining lymph nodes (TDLNs) to understand T cell priming and trafficking patterns in Renal Cell Carcinoma (RCC). Data and biospecimen collected w...
What is the current status of trial NCT07038733?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2026-01-30. Estimated completion is 2027-12.
What conditions does trial NCT07038733 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma (RCC).
What interventions are being tested in trial NCT07038733?
The interventions under investigation include: Peripheral Blood Sample for Immune Analysis (PROCEDURE), Tumor Sample for Analysis (PROCEDURE), Adjacent non-malignant kidney for analysis (PROCEDURE), Draining lymph node(s) for analysis (PROCEDURE), Regional non-draining lymph node(s) for analysis (PROCEDURE).
Who is sponsoring clinical trial NCT07038733?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07038733 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma (RCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07038733's enrollment target sits among peer trials
10 13th of 12 the lowest of 12 other Renal Cell Carcinoma (RCC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma (RCC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"
RECRUITING · NA
-
ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses
RECRUITING · NA
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RECRUITING · Phase 1
-
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
RECRUITING · Phase 3
-
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI